McKesson Reports Q2 Fiscal 2027 Growth and Outlines FY2027 EPS Guidance
McKesson (MCK) reported strong second-quarter fiscal 2027 results, highlighted by an 8% increase in revenue across all business segments. The company saw significant profitability growth, with adjusted earnings per diluted share rising 18% year-over-year. Looking ahead, McKesson provided fiscal 2027 guidance, projecting adjusted earnings per diluted share to fall between $45.60 and $46.40. This outlook comes as the company moves toward closing its $2.25 billion acquisition of Precision Medicine Group, a strategic move aimed at expanding its capabilities in specialized healthcare sectors.
Tickers: $MCK
Topics: earnings report EPS increase revenue growth
Read the full article at Seeking Alpha
Part of the story Mckesson outlines fiscal 2027 adjusted EPS of $45.60-$46.40 while closing $2.25B Precision Medicine Group deal (2 articles)